PRESS RELEASE
15 July 2020

Reed Smith Hosts July 16 Life Sciences Virtual Roundtable On “Deal Making In A Post-COVID World”

RS
Reed Smith

Contributor

While the life sciences sector has proven more resilient than most, COVID-19 has undoubtedly caused a dramatic slowdown in deal activity globally across industries.
United States
To print this article, all you need is to be registered or login on Mondaq.com.

While the life sciences sector has proven more resilient than most, COVID-19 has undoubtedly caused a dramatic slowdown in deal activity globally across industries. Please join Reed Smith and a panel of strategic, private equity, and venture capital leading deal makers for an engaging discussion on the impact COVID-19 has had on deal making in the life sciences sector, lessons learned, and their perspectives on deal making and deal trends in the sector in a post-COVID-19 world.

Our speakers include:

  • Iqbal Hussain, Life Sciences Transactional Partner, Reed Smith
  • A. Maria Dahl, Head of Transactions: Oncology Business Development & Licensing, AstraZeneca
  • Edward de Nor, Executive Parter, GHO Capital
  • Johan Verbeeck, Vice President Business Development, Immunology, Janssen Pharmaceutical Companies of Johnson & Johnson
  • Laurence Barker, Partner and CBO, Dementia Discovery Fund SV Heath Investors
  • James West, Director, Results Healthcare

You can register for the roundtable by clicking here.

PRESS RELEASE
15 July 2020

Reed Smith Hosts July 16 Life Sciences Virtual Roundtable On “Deal Making In A Post-COVID World”

United States

Contributor

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More